A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

502

Enrollment

INDUSTRY

Sponsor class

Conditions

Aortic Stenosis

Interventions

DRUG: Pelacarsen (TQJ230) 80mg
DRUG: Matching placebo

Sponsor

Novartis Pharmaceuticals